hypertriglyceridemia/obesity

FIELD OF THE INVENTION The present invention provides methods of treating obesity, sexual dysfunction (including erectile dysfunction), diabetes, insulin resistance, hyperinsulinemia, Syndrome X, adrenal dysfunction, hypertension, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia,

FIELD OF THE INVENTION The present invention provides methods of treating obesity, sexual dysfunction (including erectile dysfunction), diabetes, insulin resistance, hyperinsulinemia, Syndrome X, adrenal dysfunction, hypertension, hypercholesterolemia, atherosclerosis, hyperlipoproteinemia,

FIELD OF THE INVENTION The instant invention is concerned with acyl sulfamides and pharmaceutically acceptable salts and prodrugs thereof and their use as therapeutic. compounds, particularly in the treatment of obesity, of Type 2 diabetes mellitus (often referred to as non-insulin dependent

FIELD OF THE INVENTION The present invention relates to novel "omegastatins" or `statinized` derivatives of omega-3 fatty acids used for treating hypercholesterolemia, hypertriglyceridemia, cardiovascular diseases, metabolic diseases, inflammation, or slowing down or preventing dementia of

FIELD OF THE INVENTION The present invention relates to novel thiazolidinedione derivatives of omega-3 fatty acids used as insulin sensitizers for treating Type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic diseases, inflammation, cancer, renal anemia, Alzheimer's

FIELD OF THE INVENTION This disclosure generally relates to compounds and compositions for the treatment of diabetes and pre-diabetes. More particularly, this invention relates to treating subjects with a pharmaceutically acceptable dose of compounds, crystals, solvates, enantiomer, stereoisomer,

PRIORITY The present application claims the benefit of PCT Application No. PCT/IB2015/056704 filed on Sep. 3, 2015, which further claims benefit of Indian Provisional Patent Application No. 1436/CHE/2015 filed on Mar. 21, 2015, the entire disclosure of which is relied on for all purposes and is

BACKGROUND OF THE INVENTION Peroxisome Proliferator-Activated Receptors (PPARs) are implicated in a number of biological processes and disease states including Type 2 diabetes, hyperinsulinemia, hyperlipidemia, hyperuricemia, hypercholesteremia, atherosclerosis, one or more risk factors for

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT NOT APPLICABLE REFERENCE TO A "SEQUENCE LISTING," A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED ON A COMPACT DISK NOT APPLICABLE BACKGROUND OF THE INVENTION Peroxisome Proliferator-Activated

TECHNICAL FIELD The invention relates to the diagnosis, prevention, and/or treatment of atherosclerosis and/or underlying and/or associated diseases. BACKGROUND According to the classical view, atherosclerosis is a condition ultimately leading to the narrowing of blood vessels, impaired circulation,

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative, a preparation method thereof, and a pharmaceutical composition for the prevention and treatment of metabolic disease comprising the same as an active

FIELD OF THE INVENTION The present invention is related to aryl dicarboxamides of formula (I), in particular for the treatment and/or prevention of obsesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance,

FIELD OF THE INVENTION The present invention is related to alkynyl aryl carboxamides of formula (I') & (I), in particular for the treatment and/or prevention of obesity and/or metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate

The present invention relates to the fields of medicine and nutrition and particularly, to dietary supplements for use in weight control and in the reduction of cardiovascular negative fats. BACKGROUND ART Poor eating habits and lifestyle of our society have led to a growing public health problem.

FIELD OF THE INVENTION The present invention is related to the use of oxindole hydrazide derivatives of formula (I) for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin